News about SNCA merging with leading BioSciences.
A recently proposed merger between Seneca Biopharma and Leading BioSciences is awaiting a key vote from Seneca shareholders. For this vote to take place, shareholders must vote for a reverse stock split as well as the change in control and issuance of new shares.

Should these votes be positive, the two companies will merge, creating Palisade Bio. In the case of a merger, Seneca shareholders will own about 26% of Palisade Bio and enjoy a contingent value right, or CVR, giving shareholders rights to 80% of proceeds from Seneca Biopharma’s legacy assets.

In the video, the CEO explained that the merger would be beneficial to Seneca shareholders, who are frustrated with historical stock performance. He went on to explain that through the merger, Seneca shareholders will enjoy ownership in a company with a world-class management team, several valuable ts, and a focus on providing shareholder value.

Leading BioSciences has a strong pipeline of gastrointestinal drugs and a management team that has a strong history of performance. Moreover, not only will Seneca shareholders receive access to this management team and pipeline, should the merger be approved, shareholders will also enjoy an 80% share in legacy assets, So, you’re really not giving up much here.

BioSciences has a strong pipeline of gastrointestinal drugs and a management team that has a strong history of performance. Moreover, not only will Seneca shareholders receive access to this management team and pipeline, should the merger be approved, shareholders will also enjoy an 80% share in legacy assets, So, you’re really not giving up much here.
https://www.reddit.com/r/StockMarket/comments/mkll7j/news_about_snca_merging_with_leading_biosciences/